Clinical trialNCT01676935TerminatedPhase 2Interventional

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

SponsorAbbVie (prior sponsor, Abbott)Enrollment349Alzheimer's Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a long term extension study to evaluate safety and tolerability of subjects who complete study M10-985 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Laura Gault, MD
AbbVie
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Poland

Site Reference Id/investigator# 73514
Poznan, Poland
Site Reference Id/investigator# 73515
Szczecin, Poland

Russia

Site Reference Id/investigator# 73516
Kazan', Russia
Site Reference Id/investigator# 73525
Kazan', Russia
Site Reference Id/investigator# 73523
Kirov, Russia
Site Reference Id/investigator# 73519
Moscow, Russia
Site Reference Id/investigator# 73521
Moscow, Russia
Site Reference Id/investigator# 73517
Novosibirsk, Russia
Site Reference Id/investigator# 73518
Saint Petersburg, Russia
Site Reference Id/investigator# 73522
Saint Petersburg, Russia
Site Reference Id/investigator# 73524
Saint Petersburg, Russia
Site Reference Id/investigator# 84615
Saint Petersburg, Russia
Site Reference Id/investigator# 73520
Saratov, Russia

South Africa

Site Reference Id/investigator# 73507
Belville, South Africa
Site Reference Id/investigator# 84614
Cape Town, South Africa
Site Reference Id/investigator# 73505
George, South Africa
Site Reference Id/investigator# 73506
Johannesburg, South Africa

Ukraine

Site Reference Id/investigator# 73533
Donetsk, Ukraine
Site Reference Id/investigator# 73534
Kiev, Ukraine
Site Reference Id/investigator# 73535
Poltava, Ukraine

United Kingdom

Site Reference Id/investigator# 73502
Bath, United Kingdom
Site Reference Id/investigator# 73503
Blackburn, United Kingdom
Site Reference Id/investigator# 73501
Glasgow, United Kingdom
Site Reference Id/investigator# 73504
London, United Kingdom

United States

Site Reference Id/investigator# 73493
Delray Beach, Florida, United States
Site Reference Id/investigator# 73496
West Palm Beach, Florida, United States
Site Reference Id/investigator# 73495
Elk Grove Village, Illinois, United States
Site Reference Id/investigator# 73494
Staten Island, New York, United States
Site Reference Id/investigator# 97035
Wichita Falls, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ABT-126

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2012
Primary completion: 31 Mar 2014
Completion: 31 Mar 2014
Last update posted: 2 Aug 2021
Registered enrollment: 349
Registry id: NCT01676935

Cross-registrations

EU-CTR / CTIS (EudraCT)2011-004780-75

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.